Sponsors (22)
The bill secures multi-year funding and authority to modernize the national cord blood inventory—potentially improving transplant matches and program stability—while increasing administrative discretion and authorized federal spending that could lead to loss of specific stored units, reduced local capacity, and fiscal/appropriations uncertainty.
Hospitals, state public-health agencies, and patients: the bill maintains federal support through FY2027–2031 and increases the authorized annual funding (from $31,009,000 to $33,009,000), giving multi-year budget certainty to sustain collection, storage, and related program staffing/operations.
Patients who need stem-cell transplants: the Secretary can shape inventory size and composition based on current science, improving the chance of better-matched, clinically useful units for transplants.
Cord blood banks and hospital programs: clearer standards and funding/contract criteria may enable more efficient resource use and longer-term program stability for compliant banks.
Patients, families, and donors: some previously banked cord blood units could be discarded or transferred, meaning loss of access to specific stored units they expected to keep.
Smaller or local cord blood banks and the communities they serve: units or funding could be withdrawn from banks deemed nonoperational, reducing local collection capacity and potentially limiting access in some areas.
Banks, clinicians, and researchers: broad discretionary authority for the Secretary to set inventory targets could shift decisions based on administrative priorities, creating uncertainty about future availability and complicating clinical/research planning.
Based on analysis of 3 sections of legislative text.
Extends and increases program authorizations through 2031 and replaces a fixed cord-blood inventory target with Secretary-determined, science-based inventory management.
Reauthorizes and adjusts federal support for stem cell and cord blood programs through 2031. It preserves an existing annual authorization level for fiscal years 2022–2026, creates a higher separate authorization for fiscal years 2027–2031, and gives the HHS Secretary new discretion to manage the National Cord Blood Inventory, replacing a fixed numeric target with science- and operations-based authority. The bill revises statutory language to allow transfer or disposition of units from nonoperational or noncompliant banks, requires contract decisions to consider current scientific and clinical information, defines a "high-quality cord blood unit," and extends authorization of appropriations to FY2027–2031. Overall it shifts the program from a rigid inventory mandate to a flexible, evidence-based inventory-management approach and increases authorized funding in later years.
Official title: Stem Cell Therapeutic and Research Reauthorization Act of 2025
Introduced September 4, 2025 by Christopher Henry Smith · Last progress July 21, 2026